Literature DB >> 25296094

The use of immunoglobulin light chain assays in the diagnosis of paraprotein-related kidney disease.

Punit Yadav1, Nelson Leung2, Paul W Sanders3, Paul Cockwell1.   

Abstract

Kidney involvement is common in paraprotein-related diseases. A diversity of clinical presentations and histopathological features can occur secondary to tissue injury caused by precipitation or deposition of a clonal immunoglobulin, usually an immunoglobulin light chain. The paraprotein is either produced by multiple myeloma or by a clone of B-cell lineage that does not fulfill diagnostic criteria for multiple myeloma. The recent introduction of serum immunoglobulin free light chain assays, which accurately quantify both light chain isotypes to produce a ratio that indicates the presence or absence of a light chain paraprotein, is a major clinical development. However, as the interpretation of the assay can be challenging, the aim of this review is to clarify the role of serum and urinary light chain assays in the screening and diagnosis of paraprotein-related kidney disease.

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25296094      PMCID： PMC4863638          DOI： 10.1038/ki.2014.333

Source DB:  PubMed          Journal:  Kidney Int        ISSN： 0085-2538            Impact factor:   10.612


  28 in total

1.  Guidelines for the analysis of Bence Jones protein.

Authors:  Mariastella Graziani; Giampaolo Merlini; Concetta Petrini
Journal:  Clin Chem Lab Med       Date:  2003-03       Impact factor: 3.694

2.  Prevalence and risk of progression of light-chain monoclonal gammopathy of undetermined significance: a retrospective population-based cohort study.

Authors:  Angela Dispenzieri; Jerry A Katzmann; Robert A Kyle; Dirk R Larson; L Joseph Melton; Colin L Colby; Terry M Therneau; Raynell Clark; Shaji K Kumar; Arthur Bradwell; Rafael Fonseca; D F Jelinek; S Vincent Rajkumar
Journal:  Lancet       Date:  2010-05-15       Impact factor: 79.321

3.  Quantitation of serum free light chains in combination with protein electrophoresis and clinical information for diagnosing multiple myeloma in a general hospital population.

Authors:  Armin P Piehler; Nina Gulbrandsen; Peter Kierulf; Petter Urdal
Journal:  Clin Chem       Date:  2008-09-18       Impact factor: 8.327

4.  Urine immunofixation electrophoresis remains important and is complementary to serum free light chain.

Authors:  Stanley S Levinson
Journal:  Clin Chem Lab Med       Date:  2011-06-13       Impact factor: 3.694

Review 5.  Electrophoretic analysis of Bence Jones proteinuria.

Authors:  T Marshall; K M Williams
Journal:  Electrophoresis       Date:  1999-06       Impact factor: 3.535

6.  Serum free light chains: an alternative to the urine Bence Jones proteins screening test for monoclonal gammopathies.

Authors:  Peter G Hill; Julia M Forsyth; Baldeep Rai; Stewart Mayne
Journal:  Clin Chem       Date:  2006-07-20       Impact factor: 8.327

7.  Use of serum free light chain analysis and urine protein electrophoresis for detection of monoclonal gammopathies.

Authors:  Stephen Holding; Dorothy Spradbery; Robin Hoole; Rachel Wilmot; Michael L Shields; Alison M Levoguer; Philip C Doré
Journal:  Clin Chem Lab Med       Date:  2010-10-20       Impact factor: 3.694

Review 8.  International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders.

Authors:  A Dispenzieri; R Kyle; G Merlini; J S Miguel; H Ludwig; R Hajek; A Palumbo; S Jagannath; J Blade; S Lonial; M Dimopoulos; R Comenzo; H Einsele; B Barlogie; K Anderson; M Gertz; J L Harousseau; M Attal; P Tosi; P Sonneveld; M Boccadoro; G Morgan; P Richardson; O Sezer; M V Mateos; M Cavo; D Joshua; I Turesson; W Chen; K Shimizu; R Powles; S V Rajkumar; B G M Durie
Journal:  Leukemia       Date:  2008-11-20       Impact factor: 11.528

9.  Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.

Authors:  Jerry A Katzmann; Raynell J Clark; Roshini S Abraham; Sandra Bryant; James F Lymp; Arthur R Bradwell; Robert A Kyle
Journal:  Clin Chem       Date:  2002-09       Impact factor: 8.327

10.  Serum free light chain measurement aids the diagnosis of myeloma in patients with severe renal failure.

Authors:  Colin A Hutchison; Tim Plant; Mark Drayson; Paul Cockwell; Melpomeni Kountouri; Kolitha Basnayake; Stephen Harding; Arthur R Bradwell; Graham Mead
Journal:  BMC Nephrol       Date:  2008-09-22       Impact factor: 2.388
View more
  9 in total

Review 1.  Monoclonal gammopathy of renal significance (MGRS): the characteristics and significance of a new meta-entity.

Authors:  Mariana Ciocchini; Jorge Arbelbide; Carlos G Musso
Journal:  Int Urol Nephrol       Date:  2017-04-19       Impact factor: 2.370

2.  Renal outcome in patients with newly diagnosed multiple myeloma: results from the UK NCRI Myeloma XI trial.

Authors:  Ritika Rana; Paul Cockwell; Mark Drayson; Mark Cook; Guy Pratt; David A Cairns; Charlotte Pawlyn; Graham Jackson; Faith Davies; Gareth Morgan; Jennifer Helen Pinney
Journal:  Blood Adv       Date:  2020-11-24

Review 3.  Kidney injury and disease in patients with haematological malignancies.

Authors:  Frank Bridoux; Paul Cockwell; Ilya Glezerman; Victoria Gutgarts; Jonathan J Hogan; Kenar D Jhaveri; Florent Joly; Samih H Nasr; Deirdre Sawinski; Nelson Leung
Journal:  Nat Rev Nephrol       Date:  2021-03-30       Impact factor: 28.314

4.  Type I Cryoglobulinemic Nephritis in a Patient of Monoclonal Gammopathy of Renal Significance.

Authors:  V A Lobo; K Subramaniam; M A Bidaye; S Deshpande
Journal:  Indian J Nephrol       Date:  2018 Jan-Feb

5.  C3 glomerulonephritis associated with monoclonal gammopathy of renal significance: case report.

Authors:  Juana Alonso-Titos; Lara Perea-Ortega; Eugenia Sola; Alvaro Torres-Rueda; Myriam León; Remedios Toledo; Ana D Duarte; Teresa Vazquez; Maria Dolores Martinez-Esteban; Alicia Bailen; Pedro Ruiz-Esteban; Domingo Hernandez
Journal:  BMC Nephrol       Date:  2018-06-08       Impact factor: 2.388

Review 6.  Physiology, Diagnosis and Treatment of Cardiac Light Chain Amyloidosis.

Authors:  Agnieszka Stelmach-Gołdyś; Monika Zaborek-Łyczba; Jakub Łyczba; Bartosz Garus; Marcin Pasiarski; Paulina Mertowska; Paulina Małkowska; Rafał Hrynkiewicz; Paulina Niedźwiedzka-Rystwej; Ewelina Grywalska
Journal:  J Clin Med       Date:  2022-02-09       Impact factor: 4.241

Review 7.  Renal amyloidosis: a new time for a complete diagnosis.

Authors:  V A Feitosa; P D M M Neves; L B Jorge; I L Noronha; L F Onuchic
Journal:  Braz J Med Biol Res       Date:  2022-10-03       Impact factor: 2.904

8.  Improving the diagnostic pathway in patients presenting with acute kidney injury secondary to de novo multiple myeloma: a short report.

Authors:  Ritika Rana; Guy Pratt; Mark Cook; Mark Trehane Drayson; Karthik Ramasamy; Ross Sadler; Doreen Zhu; Thomas Connor; Jennifer Helen Pinney
Journal:  BMJ Open Qual       Date:  2021-07

9.  Multiple myeloma can be accurately diagnosed in acute kidney injury patients using a rapid serum free light chain test.

Authors:  Jennifer L J Heaney; John P Campbell; Punit Yadav; Ann E Griffin; Meena Shemar; Jennifer H Pinney; Mark T Drayson
Journal:  BMC Nephrol       Date:  2017-07-20       Impact factor: 2.388
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.